1990 - Fellow of Alfred P. Sloan Foundation
1986 - Fellow of the American Statistical Association (ASA)
His main research concerns Internal medicine, Breast cancer, Oncology, Clinical trial and Cancer. He combines topics linked to Surgery with his work on Internal medicine. His Breast cancer research includes elements of Gynecology and Paclitaxel, Chemotherapy.
His research investigates the connection between Chemotherapy and topics such as Tamoxifen that intersect with problems in Regimen. His Oncology study incorporates themes from Stage, Pathology, Proportional hazards model, Biomarker and Survival analysis. His Clinical trial research incorporates elements of Research design, Randomized controlled trial, Data mining and Personalized medicine.
Donald A. Berry mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Clinical trial. His research on Internal medicine often connects related areas such as Surgery. His work in Oncology covers topics such as Biomarker which are related to areas like Bioinformatics.
The concepts of his Breast cancer study are interwoven with issues in Stage, Gynecology and Paclitaxel. His Cancer research is multidisciplinary, relying on both Proportional hazards model and Disease. His study looks at the relationship between Clinical trial and topics such as Bayesian probability, which overlap with Econometrics.
Donald A. Berry mostly deals with Internal medicine, Oncology, Breast cancer, Cancer and Neoadjuvant therapy. His work in Trastuzumab, Randomized controlled trial, Lapatinib, Confidence interval and Paclitaxel are all subfields of Internal medicine research. His research integrates issues of Clinical endpoint, Clinical trial, Chemotherapy, Meta-analysis and Hazard ratio in his study of Oncology.
His study in the fields of MammaPrint under the domain of Breast cancer overlaps with other disciplines such as Olaparib. The various areas that Donald A. Berry examines in his Cancer study include Regimen and Cohort. Donald A. Berry has researched Neoadjuvant therapy in several fields, including Stage, Translational research, Melanoma and Clinical study design.
Donald A. Berry mainly investigates Internal medicine, Oncology, Breast cancer, Neoadjuvant therapy and Randomized controlled trial. As part of his studies on Internal medicine, he frequently links adjacent subjects like Anus. His Oncology study combines topics from a wide range of disciplines, such as Clinical endpoint, Clinical trial, Confirmatory trial, Trastuzumab and Hazard ratio.
Breast cancer is the subject of his research, which falls under Cancer. Donald A. Berry interconnects Lapatinib, Melanoma, Anal cancer and Systemic therapy in the investigation of issues within Neoadjuvant therapy. His study focuses on the intersection of Randomized controlled trial and fields such as Triple-negative breast cancer with connections in the field of Carboplatin, Long term outcomes, Bevacizumab, Chemotherapy regimen and Pembrolizumab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis.
Journal of Clinical Oncology (2003)
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione.
Journal of Clinical Oncology (2003)
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
S. Eva Singletary;Craig Allred;Pandora Ashley;Lawrence W. Bassett.
Journal of Clinical Oncology (2002)
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser.
Journal of Clinical Oncology (2005)
Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Peter B. Bach;Joshua N. Mirkin;Thomas K. Oliver;Christopher G. Azzoli.
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y Chang;Suresh Senan;Marinus A. Paul;Reza John Mehran.
Lancet Oncology (2015)
The decrease in breast-cancer incidence in 2003 in the United States
Peter M. Ravdin;Kathleen A. Cronin;Nadia Howlader;Christine D. Berg.
The New England Journal of Medicine (2007)
Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial
David J. Wilber;Carlo Pappone;Petr Neuzil;Angelo De Paola.
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Hyman B. Muss;Ann D. Thor;Donald A. Berry;Timothy Kute.
The New England Journal of Medicine (1994)
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
Kevin S. Hughes;Lauren A. Schnaper;Donald Berry;Constance Cirrincione.
The New England Journal of Medicine (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: